Royal Bank of Canada’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $102K | Buy |
4,758
+607
| +15% | +$13.1K | ﹤0.01% | 5115 |
|
|
2025
Q4 | $99K | Sell |
4,151
-36,949
| -90% | -$754K | ﹤0.01% | 5204 |
|
|
2025
Q3 | $558K | Sell |
41,100
-30,756
| -43% | -$320K | ﹤0.01% | 4405 |
|
|
2025
Q2 | $586K | Buy |
71,856
+67,651
| +1,609% | +$578K | ﹤0.01% | 4349 |
|
|
2025
Q1 | $33K | Buy |
4,205
+2,618
| +165% | +$30.4K | ﹤0.01% | 5734 |
|
|
2024
Q4 | $24K | Sell |
1,587
-4,290
| -73% | -$70.1K | ﹤0.01% | 6043 |
|
|
2024
Q3 | $90K | Buy |
5,877
+555
| +10% | +$8.75K | ﹤0.01% | 5417 |
|
|
2024
Q2 | $81K | Buy |
5,322
+4,117
| +342% | +$66.4K | ﹤0.01% | 5394 |
|
|
2024
Q1 | $23K | Sell |
1,205
-4,024
| -77% | -$69.6K | ﹤0.01% | 5862 |
|
|
2023
Q4 | $100K | Buy |
5,229
+5,211
| +28,950% | +$83.3K | ﹤0.01% | 5619 |
|
|
2023
Q3 | $0 | Hold |
18
| – | – | ﹤0.01% | 7483 |
|
|
2023
Q2 | $0 | Sell |
18
-2,969
| -99% | -$56.5K | ﹤0.01% | 7585 |
|
|
2023
Q1 | $54K | Sell |
2,987
-16,572
| -85% | -$317K | ﹤0.01% | 5584 |
|
|
2022
Q4 | $405K | Buy |
19,559
+4,080
| +26% | +$112K | ﹤0.01% | 4293 |
|
|
2022
Q3 | $404K | Buy |
15,479
+14,973
| +2,959% | +$396K | ﹤0.01% | 4204 |
|
|
2022
Q2 | $12K | Sell |
506
-2,266
| -82% | -$55.5K | ﹤0.01% | 6318 |
|
|
2022
Q1 | $88K | Sell |
2,772
-4,743
| -63% | -$159K | ﹤0.01% | 5744 |
|
|
2021
Q4 | $305K | Buy |
+7,515
| New | +$292K | ﹤0.01% | 4916 |
|
|
2021
Q3 | – | Sell |
-3,102
| Closed | -$85K | – | 7821 |
|
|
2021
Q2 | $85K | Buy |
3,102
+2,124
| +217% | +$60.7K | ﹤0.01% | 5719 |
|
|
2021
Q1 | $27K | Buy |
+978
| New | +$34K | ﹤0.01% | 6256 |
|
|
2020
Q4 | – | Sell |
-73
| Closed | -$1K | – | 7249 |
|
|
2020
Q3 | $1K | Sell |
73
-16
| -18% | -$357 | ﹤0.01% | 6469 |
|
|
2020
Q2 | $3K | Sell |
89
-75
| -46% | -$2.02K | ﹤0.01% | 6205 |
|
|
2020
Q1 | $2K | Sell |
164
-3,158
| -95% | -$39.3K | ﹤0.01% | 6323 |
|
|
2019
Q4 | $33K | Buy |
3,322
+833
| +33% | +$7K | ﹤0.01% | 5644 |
|
|
2019
Q3 | $23K | Buy |
2,489
+889
| +56% | +$7.14K | ﹤0.01% | 5448 |
|
|
2019
Q2 | $13K | Buy |
1,600
+600
| +60% | +$6.01K | ﹤0.01% | 5933 |
|
|
2019
Q1 | $12K | Hold |
1,000
| – | – | ﹤0.01% | 5905 |
|
|
2018
Q4 | $11K | Sell |
1,000
-362
| -27% | -$4.23K | ﹤0.01% | 5849 |
|
|
2018
Q3 | $19K | Buy |
1,362
+1,342
| +6,710% | +$17.1K | ﹤0.01% | 5708 |
|
|
2018
Q2 | $0 | Buy |
+20
| New | +$314 | ﹤0.01% | 6717 |
|
Other funds holding RCUS
GS
SCM
VPM
VCM
WP
SL
Royal Bank of Canada's RCUS Position: Q1 2026 in Review
Royal Bank of Canada increased its Arcus Biosciences (RCUS) stake by 15% in Q1 2026, buying an estimated $13.1K and bringing the position to 4,758 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #5115.
Royal Bank of Canada first reported a position in RCUS in Q2 2018 and has held it in 30 quarters since. The position peaked at $586K in Q2 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.
- Royal Bank of Canada held 4,758 shares of Arcus Biosciences worth $102K as of Q1 2026.
- Royal Bank of Canada bought 607 Arcus Biosciences shares in Q1 2026, an estimated $13.1K.
- Arcus Biosciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5115 holding.
- Royal Bank of Canada first reported a position in Arcus Biosciences in Q2 2018 and has held it in 30 quarters since.
- Royal Bank of Canada's Arcus Biosciences position peaked at $586K in Q2 2025.
- 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.